SEI Investments’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $131M | Buy |
757,129
+371
| +0% | +$68.8K | 0.12% | 181 |
|
|
2025
Q4 | $151M | Buy |
756,758
+7,035
| +0.9% | +$1.28M | 0.15% | 130 |
|
|
2025
Q3 | $117M | Buy |
749,723
+35,035
| +5% | +$5.56M | 0.13% | 153 |
|
|
2025
Q2 | $108M | Buy |
714,688
+46,510
| +7% | +$6.2M | 0.13% | 167 |
|
|
2025
Q1 | $101M | Sell |
668,178
-5,690
| -0.8% | -$954K | 0.13% | 160 |
|
|
2024
Q4 | $124M | Buy |
673,868
+38,827
| +6% | +$7.48M | 0.16% | 128 |
|
|
2024
Q3 | $125M | Buy |
635,041
+10,241
| +2% | +$2.13M | 0.16% | 120 |
|
|
2024
Q2 | $129M | Buy |
624,800
+49,451
| +9% | +$11.2M | 0.18% | 105 |
|
|
2024
Q1 | $156M | Buy |
575,349
+7,142
| +1% | +$1.71M | 0.23% | 82 |
|
|
2023
Q4 | $134M | Buy |
568,207
+110,494
| +24% | +$21.7M | 0.22% | 84 |
|
|
2023
Q3 | $89.7M | Sell |
457,713
-49,412
| -10% | -$10.1M | 0.16% | 110 |
|
|
2023
Q2 | $107M | Buy |
507,125
+5,947
| +1% | +$1.18M | 0.19% | 96 |
|
|
2023
Q1 | $101M | Buy |
501,178
+66,897
| +15% | +$15.2M | 0.19% | 93 |
|
|
2022
Q4 | $94.6M | Buy |
434,281
+1,482
| +0.3% | +$324K | 0.21% | 83 |
|
|
2022
Q3 | $85.2M | Buy |
432,799
+242,528
| +127% | +$52.4M | 0.19% | 87 |
|
|
2022
Q2 | $40.7M | Buy |
190,271
+95,402
| +101% | +$23.3M | 0.09% | 243 |
|
|
2022
Q1 | $27M | Buy |
94,869
+1,104
| +1% | +$340K | 0.05% | 381 |
|
|
2021
Q4 | $35.4M | Sell |
93,765
-2,874
| -3% | -$1.12M | 0.07% | 306 |
|
|
2021
Q3 | $39.8M | Sell |
96,639
-26,975
| -22% | -$11.2M | 0.08% | 247 |
|
|
2021
Q2 | $45.7M | Sell |
123,614
-13,771
| -10% | -$4.6M | 0.1% | 193 |
|
|
2021
Q1 | $39.6M | Sell |
137,385
-16,184
| -11% | -$4.5M | 0.1% | 197 |
|
|
2020
Q4 | $38.4M | Sell |
153,569
-13,348
| -8% | -$3.18M | 0.1% | 198 |
|
|
2020
Q3 | $37.8M | Sell |
166,917
-22,063
| -12% | -$4.58M | 0.11% | 164 |
|
|
2020
Q2 | $32.9M | Sell |
188,980
-15,382
| -8% | -$2.45M | 0.1% | 182 |
|
|
2020
Q1 | $25.8M | Buy |
204,362
+17,468
| +9% | +$2.62M | 0.09% | 204 |
|
|
2019
Q4 | $28.4M | Sell |
186,894
-15,992
| -8% | -$2.21M | 0.08% | 227 |
|
|
2019
Q3 | $26.8M | Buy |
202,886
+4,460
| +2% | +$598K | 0.07% | 261 |
|
|
2019
Q2 | $28.2M | Buy |
198,426
+4,152
| +2% | +$563K | 0.09% | 218 |
|
|
2019
Q1 | $28.2M | Sell |
194,274
-2,674
| -1% | -$351K | 0.09% | 212 |
|
|
2018
Q4 | $26.2M | Sell |
196,948
-5,453
| -3% | -$683K | 0.09% | 219 |
|
|
2018
Q3 | $27.2M | Buy |
202,401
+25,034
| +14% | +$3.09M | 0.1% | 198 |
|
|
2018
Q2 | $19.9M | Buy |
177,367
+12,618
| +8% | +$1.36M | 0.07% | 296 |
|
|
2018
Q1 | $17.6M | Sell |
164,749
-4,461
| -3% | -$481K | 0.07% | 303 |
|
|
2017
Q4 | $18.5M | Buy |
169,210
+5,640
| +3% | +$614K | 0.06% | 352 |
|
|
2017
Q3 | $17.7M | Buy |
163,570
+53,105
| +48% | +$5.46M | 0.06% | 347 |
|
|
2017
Q2 | $11.2M | Buy |
110,465
+12,424
| +13% | +$1.14M | 0.04% | 505 |
|
|
2017
Q1 | $8.82M | Buy |
98,041
+1,242
| +1% | +$105K | 0.04% | 565 |
|
|
2016
Q4 | $7.38M | Buy |
96,799
+14,193
| +17% | +$1.08M | 0.04% | 601 |
|
|
2016
Q3 | $6.88M | Buy |
82,606
+4,735
| +6% | +$397K | 0.04% | 572 |
|
|
2016
Q2 | $6.42M | Buy |
77,871
+689
| +0.9% | +$56.8K | 0.04% | 570 |
|
|
2016
Q1 | $5.86M | Sell |
77,182
-3,148
| -4% | -$233K | 0.04% | 574 |
|
|
2015
Q4 | $6.46M | Buy |
80,330
+38,796
| +93% | +$2.8M | 0.04% | 560 |
|
|
2015
Q3 | $2.64M | Buy |
41,534
+7,325
| +21% | +$526K | 0.02% | 681 |
|
|
2015
Q2 | $2.41M | Buy |
34,209
+212
| +0.6% | +$15.7K | 0.02% | 685 |
|
|
2015
Q1 | $2.7M | Buy |
33,997
+3,056
| +10% | +$225K | 0.02% | 639 |
|
|
2014
Q4 | $1.97M | Buy |
+30,941
| New | +$1.94M | 0.02% | 707 |
|
Other funds holding CRL
VCM
VPM
SEI Investments's CRL Position: Q1 2026 in Review
SEI Investments increased its Charles River Laboratories (CRL) stake by 0.05% in Q1 2026, buying an estimated $68.8K and bringing the position to 757,129 shares worth $131M. The position accounts for 0.12% of the portfolio, ranked #181.
SEI Investments first reported a position in CRL in Q4 2014 and has held it in 46 quarters since. The position peaked at $156M in Q1 2024. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- SEI Investments held 757,129 shares of Charles River Laboratories worth $131M as of Q1 2026.
- SEI Investments bought 371 Charles River Laboratories shares in Q1 2026, an estimated $68.8K.
- Charles River Laboratories made up 0.12% of SEI Investments's portfolio in Q1 2026, its #181 holding.
- SEI Investments first reported a position in Charles River Laboratories in Q4 2014 and has held it in 46 quarters since.
- SEI Investments's Charles River Laboratories position peaked at $156M in Q1 2024.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.